All articles by Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
Robert Barrie
AI should “augment, not replace” pathologists, says expert
AI-powered digital pathology is transforming disease diagnosis, but professor of pathology Liron Pantanowitz says the software cannot go it alone.
Drug manufacturing automation key as populations age, says Lotte Biologics CEO
The biologics manufacturing company’s CEO said robotics and AI adoption in biopharma needs to catch up to other industries.
Awell raises $5m for clinical workflow digital platform
Investors in the seed round included Octopus Ventures, S16 and former NHS-chair Lord David Prior.
Wireless brain implant for mental health treatment tested in human
The implant, which stimulates brain circuits via a wireless headset, is designed to have minimal side effects compared to pharmaceutical drugs.
Field Medical raises $14m for cardiac ablation technology
The company aims to develop a new generation of pulsed field ablation, in a catheter ablation market expected to grow to $4.2bn by 2033.
FDA clears Attune Medical device for prevention of ablation-related oesophageal injury
The device allows surgeons to proactively control temperature to reduce the risk of oesophageal injury during cardiac ablation procedures.
PathMaker begins testing non-invasive neuromodulation device in ALS patients
Non-invasive neuromodulation therapy could provide an alternative option to pharmaceutical treatment for the neurodegenerative disease.
Meet Tara: the new AI clinical trial matcher for cancer patients
Belong.Life launches its matching platform to connect cancer patients with clinical trials to access potentially life-saving treatment.
Two FDA wins for Annalise.ai’s hydrocephalus triage tool
The FDA has granted 510(k) clearance and breakthrough device designation to the company’s obstructive hydrocephalus CT scan software.
FDA tags Mallinckrodt’s one-way valve recall as Class I
The recall involved 1,799 packs of five valves in the US distributed from January 2022 to July 2023.